| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Circulation, Vol 90, 195-203, Copyright © 1994 by American Heart Association
H Yasue, M Yoshimura, H Sumida, K Kikuta, K Kugiyama, M Jougasaki, H Ogawa, K Okumura, M Mukoyama and K Nakao
BACKGROUND: B-type or brain natriuretic peptide (BNP) is a novel
natriuretic peptide secreted from the heart that forms a peptide family
with A-type or atrial natriuretic peptide (ANP), and its plasma level has
been shown to be increased in patients with congestive heart failure. This
study was designed to examine the sources and mechanisms of the secretion
of BNP in comparison with those of ANP in control subjects and in patients
with heart failure. METHODS AND RESULTS: We measured the plasma levels of
BNP as well as ANP in 16 patients with dilated cardiomyopathy (11 men and 5
women; mean age, 59 years) and 18 control subjects (9 men and 9 women; mean
age, 54 years) by sampling blood from the femoral vein, the aortic root,
the anterior interventricular vein (AIV), and the coronary sinus using the
newly developed immunoradiometric assay systems. In the control subjects,
there was no significant difference in the plasma ANP level between the
aortic root and the AIV (24.0 +/- 5.2 pg/mL versus 32.2 +/- 17.0 pg/mL),
but there was a highly significant step-up of the level between the AIV and
the coronary sinus (32.2 +/- 17.0 pg/mL versus 371.4 +/- 111.1 pg/mL, P
< .001). In contrast, there was a significant step-up of the plasma BNP
level between the aortic root and the AIV (8.6 +/- 6.4 pg/mL versus 19.0
+/- 11.5 pg/mL, P < .01) but not between the AIV and the coronary sinus
(19.0 +/- 11.5 pg/mL versus 28.8 +/- 14.0 pg/mL). On the other hand, in
patients with dilated cardiomyopathy, there was a significant step-up in
the plasma ANP level between the aortic root and the AIV (280.6 +/- 183.7
pg/mL versus 612.3 +/- 431.6 pg/mL, P < .01) and between the AIV and the
coronary sinus (612.3 +/- 431.6 pg/mL versus 1229.0 +/- 772.7 pg/mL, P <
.01). There was a significant step- up in the plasma BNP level between the
aortic root and the AIV (268.4 +/- 293.2 pg/mL versus 511.6 +/- 458.1
pg/mL, P < .01) but not between the AIV and the coronary sinus (511.6
+/- 458.1 pg/mL versus 529.7 +/- 455.3 pg/mL) in patients with dilated
cardiomyopathy. The arteriovenous difference at the AIV of the plasma level
of BNP had a significant positive correlation with left ventricular
end-systolic volume index (r = 0.859, P < .001) and a significant
negative correlation with left ventricular ejection fraction (r = -.735, P
< .001). CONCLUSIONS: We conclude that (1) BNP is secreted mainly from
the left ventricle in normal adult humans as well as in patients with left
ventricular dysfunction, whereas ANP is secreted from atria in normal adult
humans and also from the left ventricle in patients with left ventricular
dysfunction; (2) secretion of BNP as well as ANP from the left ventricle
increases in proportion to the severity of the left ventricular
dysfunction, suggesting that the secretions of ANP and BNP from the left
ventricle are regulated mainly by wall tension of the left ventricle; and
(3) the peripheral plasma levels of ANP and BNP reflect the secretion rate
of these hormones from the left ventricle and may be used as a marker of
the degree of left ventricular dysfunction in patients with left
ventricular dysfunction.
ARTICLES
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure
Division of Cardiology, Kumamoto University School of Medicine, Japan.
This article has been cited by other articles:
 |
|
 |
|
  M. S. Kallistratos, A. Dritsas, I. D. Laoutaris, and D. V. Cokkinos N-terminal Prohormone Brain Natriuretic Peptide Plasma Levels in Heart Failure Are Affected Both Directly and Indirectly by Carvedilol Angiology, July 1, 2008; 59(3): 323 - 328. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Roberts, P. M. Srivastava, N. Macmillan, D. L. Hare, S. Ratnaike, K. Sikaris, and F. L. Ierino B-type Natriuretic Peptides Strongly Predict Mortality in Patients Who Are Treated with Long-Term Dialysis Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1057 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nishii, T. Inomata, H. Takehana, T. Naruke, T. Yanagisawa, M. Moriguchi, S. Takeda, and T. Izumi Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2329 - 2335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Waldo, J. Beede, S. Isakson, S. Villard-Saussine, J. Fareh, P. Clopton, R. L. Fitzgerald, and A. S. Maisel Pro-B-Type Natriuretic Peptide Levels in Acute Decompensated Heart Failure J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1874 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Sacher, J.-B. Corcuff, P. Schraub, V. Le Bouffos, A. Georges, S. O. Jones, S. Lafitte, P. Bordachar, M. Hocini, J. Clementy, et al. Chronic atrial fibrillation ablation impact on endocrine and mechanical cardiac functions Eur. Heart J., May 2, 2008; 29(10): 1290 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kandil, J. Burack, A. Sawas, H. Bibawy, A. Schwartzman, M. E. Zenilman, and M. H. Bluth B-Type Natriuretic Peptide: A Biomarker for the Diagnosis and Risk Stratification of Patients With Septic Shock Arch Surg, March 1, 2008; 143(3): 242 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Daniels and A. S. Maisel Natriuretic Peptides J. Am. Coll. Cardiol., December 18, 2007; 50(25): 2357 - 2368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kasama, T. Toyama, H. Sumino, N. Matsumoto, Y. Sato, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi Additive Effects of Spironolactone and Candesartan on Cardiac Sympathetic Nerve Activity and Left Ventricular Remodeling in Patients with Congestive Heart Failure J. Nucl. Med., December 1, 2007; 48(12): 1993 - 2000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A Pascual-Figal, M. J Antolinos, A. Bayes-Genis, T. Casas, F. Nicolas, and M. Valdes B-type natriuretic peptide release in the coronary effluent after acute transient ischaemia in humans Heart, September 1, 2007; 93(9): 1077 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jourdain, G. Jondeau, F. Funck, P. Gueffet, A. Le Helloco, E. Donal, J. F. Aupetit, M. C. Aumont, M. Galinier, J. C. Eicher, et al. Plasma Brain Natriuretic Peptide-Guided Therapy to Improve Outcome in Heart Failure: The STARS-BNP Multicenter Study J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1733 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kasama, T. Toyama, T. Hatori, H. Sumino, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol Eur. Heart J., April 4, 2007; (2007) ehm048v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Brown, M. D. Abel, R. L. Click, R. G. Morford, J. A. Dearani, T. M. Sundt, T. A. Orszulak, and H. V. Schaff Systolic anterior motion after mitral valve repair: Is surgical intervention necessary? J. Thorac. Cardiovasc. Surg., January 1, 2007; 133(1): 136 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Takano, Y. Kodama, Y. Kitta, T. Nakamura, J.-e. Obata, A. Mende, K.-i. Kawabata, Y. Saitoh, D. Fujioka, T. Kobayashi, et al. Transcardiac adiponectin gradient is independently related to endothelial vasomotor function in large and resistance coronary arteries in humans Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2641 - H2646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Kasama, T Toyama, T Hatori, H Sumino, H Kumakura, Y Takayama, S Ichikawa, T Suzuki, and M Kurabayashi Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure Heart, October 1, 2006; 92(10): 1434 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Takahashi, H. Takase, T. Toriyama, T. Sugiura, Y. Kurita, R. Ueda, and Y. Dohi Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2507 - 2512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Norager, M Husic, J E Moller, A Bo Hansen, P A Pellikka, and K Egstrup Changes in the Doppler myocardial performance index during dobutamine echocardiography: association with neurohormonal activation and prognosis after acute myocardial infarction Heart, August 1, 2006; 92(8): 1071 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Giuliani, F. Rieunier, C. Larue, J.-F. Delagneau, C. Granier, B. Pau, M. Ferriere, M. Saussine, J.-P. Cristol, A.-M. Dupuy, et al. Assay for Measurement of Intact B-Type Natriuretic Peptide Prohormone in Blood Clin. Chem., June 1, 2006; 52(6): 1054 - 1061. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mueller, K. Laule-Kilian, C. Schindler, T. Klima, B. Frana, D. Rodriguez, A. Scholer, M. Christ, and A. P. Perruchoud Cost-effectiveness of B-Type Natriuretic Peptide Testing in Patients With Acute Dyspnea. Arch Intern Med, May 22, 2006; 166(10): 1081 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Kasama, T Toyama, T Hatori, H Sumino, H Kumakura, Y Takayama, S Ichikawa, T Suzuki, and M Kurabayashi Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure Heart, May 1, 2006; 92(5): 625 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Watanabe, J. Shite, H. Takaoka, T. Shinke, Y. Imuro, T. Ozawa, H. Otake, D. Matsumoto, D. Ogasawara, O. L. Paredes, et al. Myocardial stiffness is an important determinant of the plasma brain natriuretic peptide concentration in patients with both diastolic and systolic heart failure Eur. Heart J., April 1, 2006; 27(7): 832 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cosgrave, J. B. Foley, E. McGovern, K. Bennett, V. Young, M. Tolan, P. Crean, and M. Walsh Brain natriuretic peptide elevation and the development of atrial fibrillation following coronary artery bypass surgery Interactive CardioVascular and Thoracic Surgery, April 1, 2006; 5(2): 111 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kido, N. Hasebe, Y. Ishii, and K. Kikuchi Tachycardia-induced myocardial ischemia and diastolic dysfunction potentiate secretion of ANP, not BNP, in hypertrophic cardiomyopathy Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1064 - H1070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Iwanaga, I. Nishi, S. Furuichi, T. Noguchi, K. Sase, Y. Kihara, Y. Goto, and H. Nonogi B-Type Natriuretic Peptide Strongly Reflects Diastolic Wall Stress in Patients With Chronic Heart Failure: Comparison Between Systolic and Diastolic Heart Failure J. Am. Coll. Cardiol., February 21, 2006; 47(4): 742 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nohria and M. M. Givertz B-Type Natriuretic Peptide and the Stressed Heart J. Am. Coll. Cardiol., February 21, 2006; 47(4): 749 - 751. [Full Text] [PDF]
|
|
|
|
|
|
S. D.R. Thackray, K. Witte, J. Ghosh, N. Nikitin, A. Anderson, A. Rigby, K. Goode, A. L. Clark, and J. G.F. Cleland N-terminal brain natriuretic peptide as a screening tool for heart failure in the pacemaker population Eur. Heart J., February 2, 2006; 27(4): 447 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nishikimi, N. Maeda, and H. Matsuoka The role of natriuretic peptides in cardioprotection Cardiovasc Res, February 1, 2006; 69(2): 318 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Hirayama, H Kusuoka, H Yamamoto, Y Sakata, M Asakura, Y Higuchi, H Mizuno, K Kashiwase, Y Ueda, Y Okuyama, et al. Serial changes in plasma brain natriuretic peptide concentration at the infarct and non-infarct sites in patients with left ventricular remodelling after myocardial infarction Heart, December 1, 2005; 91(12): 1573 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ferrier, A. Campbell, B. Yee, M. Richards, T. O'Meeghan, M. Weatherall, and A. Neill Sleep-Disordered Breathing Occurs Frequently in Stable Outpatients With Congestive Heart Failure Chest, October 1, 2005; 128(4): 2116 - 2122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Giannitsis and H. A. Katus Risk Stratification in Pulmonary Embolism Based on Biomarkers and Echocardiography Circulation, September 13, 2005; 112(11): 1520 - 1521. [Full Text] [PDF]
|
|
|
|
|
|
C. W. Knudsen, T. Omland, P. Clopton, A. Westheim, A. H.B. Wu, P. Duc, J. McCord, R. M. Nowak, J. E. Hollander, A. B. Storrow, et al. Impact of Atrial Fibrillation on the Diagnostic Performance of B-Type Natriuretic Peptide Concentration in Dyspneic Patients: An Analysis From the Breathing Not Properly Multinational Study J. Am. Coll. Cardiol., September 6, 2005; 46(5): 838 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Quigley Prevention of Systolic Anterior Motion After Repair of the Severely Myxomatous Mitral Valve With an Anterior Leaflet Valvuloplasty Ann. Thorac. Surg., July 1, 2005; 80(1): 179 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Steg, L. Joubin, J. McCord, W. T. Abraham, J. E. Hollander, T. Omland, F. Mentre, P. A. McCullough, A. S. Maisel, and for the Breathing Not Properly Multinational Study B-Type Natriuretic Peptide and Echocardiographic Determination of Ejection Fraction in the Diagnosis of Congestive Heart Failure in Patients With Acute Dyspnea Chest, July 1, 2005; 128(1): 21 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Reyes, G. Fores, R. Hugo Rodriguez-Abella, G. Cuerpo, J. L. Vallejo, C. Romero, and A. Pinto NT-proBNP in cardiac surgery: a new tool for the management of our patients? Interactive CardioVascular and Thoracic Surgery, June 1, 2005; 4(3): 242 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Detaint, D. Messika-Zeitoun, J.-F. Avierinos, C. Scott, H. Chen, J. C. Burnett Jr, and M. Enriquez-Sarano B-Type Natriuretic Peptide in Organic Mitral Regurgitation: Determinants and Impact on Outcome Circulation, May 10, 2005; 111(18): 2391 - 2397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.M. Makikallio, T.H. Makikallio, J.T. Korpelainen, O. Vuolteenaho, J.M. Tapanainen, K. Ylitalo, K.A. Sotaniemi, H.V. Huikuri, and V.V. Myllyla Natriuretic Peptides and Mortality After Stroke Stroke, May 1, 2005; 36(5): 1016 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction J. Am. Coll. Cardiol., March 1, 2005; 45(5): 661 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Choi, K. H. Lee, B. L. Eun, K. H. Yoo, Y. S. Hong, C. S. Son, and J. W. Lee Utility of Rapid B-Type Natriuretic Peptide Assay for Diagnosis of Symptomatic Patent Ductus Arteriosus in Preterm Infants Pediatrics, March 1, 2005; 115(3): e255 - e261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Jarai, N. Iordanova, R. Jarai, A. Raffetseder, W. Woloszczuk, M. Gyongyosi, G. Geyer, J. Wojta, and K. Huber Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide Eur. Heart J., February 1, 2005; 26(3): 250 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bassan, A. Potsch, A. Maisel, B. Tura, H. Villacorta, M. V. Nogueira, A. Campos, R. Gamarski, A. C. Masetto, and M. A. Moutinho B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation Eur. Heart J., February 1, 2005; 26(3): 234 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Vanderheyden, M. Goethals, S. Verstreken, B. De Bruyne, K. Muller, E. Van Schuerbeeck, and J. Bartunek Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2349 - 2354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Foote, J. D. Pearlman, A. H. Siegel, and K.-T. J. Yeo Detection of exercise-induced ischemia by changes in B-type natriuretic peptides J. Am. Coll. Cardiol., November 16, 2004; 44(10): 1980 - 1987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, S. Tange, T. Suzuki, and M. Kurabayashi Dobutamine Stress 99mTc-Tetrofosmin Quantitative Gated SPECT Predicts Improvement of Cardiac Function After Carvedilol Treatment in Patients with Dilated Cardiomyopathy J. Nucl. Med., November 1, 2004; 45(11): 1878 - 1884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ghio, A. D. Matteo, L. Scelsi, C. Klersy, P. Orsolini, L. Monti, C. Campana, L. Minoli, and L. Tavazzi Plasma brain natriuretic peptide is a marker of right ventricular overload in pulmonary hypertension associated to HIV infection Eur. Heart J. Suppl., November 1, 2004; 6(suppl_F): F35 - F39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Yap, D. Mukerjee, P. M. Timms, H. Ashrafian, and J. G. Coghlan Natriuretic Peptides, Respiratory Disease, and the Right Heart Chest, October 1, 2004; 126(4): 1330 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Suzuki, M. Yoshimura, M. Nakayama, Y. Mizuno, E. Harada, T. Ito, S. Nakamura, K. Abe, M. Yamamuro, T. Sakamoto, et al. Plasma Level of B-Type Natriuretic Peptide as a Prognostic Marker After Acute Myocardial Infarction: A Long-Term Follow-Up Analysis Circulation, September 14, 2004; 110(11): 1387 - 1391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.J. Akashi, H. Musha, K. Nakazawa, and F. Miyake Plasma brain natriuretic peptide in takotsubo cardiomyopathy QJM, September 1, 2004; 97(9): 599 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Rodeheffer Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004? J. Am. Coll. Cardiol., August 18, 2004; 44(4): 740 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nishikimi, H. Matsuoka, W.H. W. Tang, R. C. Starling, J. B. Young, G. S. Francis, J. P. Girod, M. J. Lee, and F. Van Lente Plasma Brain Natriuretic Peptide Levels Indicate the Distance From Decompensated Heart Failure * Response Circulation, June 29, 2004; 109(25): e329 - e330. [Full Text] [PDF]
|
|
|
|
|
|
J. Hokamaki, H. Kawano, M. Yoshimura, H. Soejima, S. Miyamoto, I. Kajiwara, S. Kojima, T. Sakamoto, S. Sugiyama, N. Hirai, et al. Urinary biopyrrins levels are elevated in relation to severity of heart failure J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1880 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shimpo, D. A. Morrow, E. O. Weinberg, M. S. Sabatine, S. A. Murphy, E. M. Antman, and R. T. Lee Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction Circulation, May 11, 2004; 109(18): 2186 - 2190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Bazzino, J. J Fuselli, F. Botto, D. Perez de Arenaza, C. Bahit, J. Dadone, and for the PACS group of investigators Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes Eur. Heart J., May 2, 2004; 25(10): 859 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Schamberger Is There a Use for Nesiritide in Pediatric Patients? J Intensive Care Med, May 1, 2004; 19(3): 171 - 173. [PDF]
|
|
|
|
|
|
J. M. Tapanainen, K. S. Lindgren, T. H. Makikallio, O. Vuolteenaho, J. Leppaluoto, and H. V. Huikuri Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era J. Am. Coll. Cardiol., March 3, 2004; 43(5): 757 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mueller, A. Scholer, K. Laule-Kilian, B. Martina, C. Schindler, P. Buser, M. Pfisterer, and A. P. Perruchoud Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute Dyspnea N. Engl. J. Med., February 12, 2004; 350(7): 647 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-Y. Marie, P. M. Mertes, N. Hassan-Sebbag, N. de Talence, K. Djaballah, W. Djaballah, J. Friberg, P. Olivier, G. Karcher, F. Zannad, et al. Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers J. Am. Coll. Cardiol., February 4, 2004; 43(3): 353 - 359. [Abstract] |